Abeona Therapeutics Inc. (ABEO) stock
ABEONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 8/3039% below fair value
$2.42+0.13 (+5.68%)
Close on Nov 13, 2026Market cap $138.39MP/E –Yield –
Abeona Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Abeona Therapeutics's R&D Expenses for the twelve months ending Sep 30, 2026 was $24.96M, down 14.2% year over year. For fiscal 2025 it was $26.81M, down 22.0% from the year before. Over ten years it grew 19.0% a year on average. The highest annual figure on record is $48.57M in fiscal 2019.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $26.81M | -22.0% |
| FY2024 | Dec 31, 2024 | $34.36M | +10.5% |
| FY2023 | Dec 31, 2023 | $31.09M | +7.3% |
| FY2022 | Dec 31, 2022 | $28.97M | -25.2% |
| FY2021 | Dec 31, 2021 | $38.73M | +28.5% |
| FY2020 | Dec 31, 2020 | $30.14M | -37.9% |
| FY2019 | Dec 31, 2019 | $48.57M | +25.5% |
| FY2018 | Dec 31, 2018 | $38.70M | +127.8% |
| FY2017 | Dec 31, 2017 | $16.99M | +59.4% |
| FY2016 | Dec 31, 2016 | $10.66M | +126.0% |
| FY2015 | Dec 31, 2015 | $4.72M | +1315.9% |
| FY2014 | Dec 31, 2014 | $333.00K | -62.3% |
| FY2013 | Dec 31, 2013 | $884.00K | -56.0% |
| FY2012 | Dec 31, 2012 | $2.01M | -43.8% |
| FY2011 | Dec 31, 2011 | $3.58M | +6.9% |
| FY2010 | Dec 31, 2010 | $3.35M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $3.67M | -12.9% |
| Q2 FY2026 | Jun 30, 2026 | $5.02M | -15.5% |
| Q1 FY2026 | Mar 31, 2026 | $9.56M | -3.9% |
| Q4 FY2025 | Dec 31, 2025 | $6.71M | -25.4% |
| Q3 FY2025 | Sep 30, 2025 | $4.22M | -52.8% |
| Q2 FY2025 | Jun 30, 2025 | $5.94M | -35.5% |
| Q1 FY2025 | Mar 31, 2025 | $9.94M | +37.9% |
| Q4 FY2024 | Dec 31, 2024 | $8.99M | +21.9% |
| Q3 FY2024 | Sep 30, 2024 | $8.94M | +25.1% |
| Q2 FY2024 | Jun 30, 2024 | $9.22M | +8.2% |
| Q1 FY2024 | Mar 31, 2024 | $7.21M | -10.4% |
| Q4 FY2023 | Dec 31, 2023 | $7.38M | +17.6% |
| Q3 FY2023 | Sep 30, 2023 | $7.15M | +30.2% |
| Q2 FY2023 | Jun 30, 2023 | $8.52M | +28.0% |
| Q1 FY2023 | Mar 31, 2023 | $8.04M | -23.7% |
| Q4 FY2022 | Dec 31, 2022 | $6.27M | -51.0% |
| Q3 FY2022 | Sep 30, 2022 | $5.49M | -39.4% |
| Q2 FY2022 | Jun 30, 2022 | $6.66M | -22.0% |
| Q1 FY2022 | Mar 31, 2022 | $10.55M | +26.8% |
| Q4 FY2021 | Dec 31, 2021 | $12.80M | +38.5% |
| Q3 FY2021 | Sep 30, 2021 | $9.06M | +13.6% |
| Q2 FY2021 | Jun 30, 2021 | $8.53M | +39.7% |
| Q1 FY2021 | Mar 31, 2021 | $8.32M | +22.0% |
| Q4 FY2020 | Dec 31, 2020 | $9.24M | -3.8% |
| Q3 FY2020 | Sep 30, 2020 | $7.97M | -27.0% |
| Q2 FY2020 | Jun 30, 2020 | $6.11M | -62.5% |
| Q1 FY2020 | Mar 31, 2020 | $6.82M | -41.9% |
| Q4 FY2019 | Dec 31, 2019 | $9.61M | +1.4% |
| Q3 FY2019 | Sep 30, 2019 | $10.92M | -17.0% |
| Q2 FY2019 | Jun 30, 2019 | $16.31M | +106.0% |
| Q1 FY2019 | Mar 31, 2019 | $11.74M | +43.8% |
| Q4 FY2018 | Dec 31, 2018 | $9.47M | +66.0% |
| Q3 FY2018 | Sep 30, 2018 | $13.15M | +301.3% |
| Q2 FY2018 | Jun 30, 2018 | $7.92M | +36.3% |
| Q1 FY2018 | Mar 31, 2018 | $8.16M | +271.3% |
| Q4 FY2017 | Dec 31, 2017 | $5.71M | +87.9% |
| Q3 FY2017 | Sep 30, 2017 | $3.28M | – |
| Q2 FY2017 | Jun 30, 2017 | $5.81M | – |
| Q1 FY2017 | Mar 31, 2017 | $2.20M | – |
| Q4 FY2016 | Dec 31, 2016 | $3.04M | – |
See a number that looks wrong?